Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves Pfizer’s Tukysa regimen for metastatic breast cancer
The regimen is indicated for adults with unresectable locally advanced or metastatic HER2+ disease following induction treatment. Credit: Arif biswas/Shutterstock.com.
The regimen is indicated for adults with unresectable locally advanced or metastatic HER2+ disease following induction treatment. Credit: Arif biswas/Shutterstock.com.